Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types.
Saved in:
| Title: | Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. |
|---|---|
| Authors: | Topham JT; Pancreas Centre BC, Vancouver, British Columbia, Canada., Titmuss E; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., Pleasance ED; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., Williamson LM; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., Karasinska JM; Pancreas Centre BC, Vancouver, British Columbia, Canada., Culibrk L; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., Lee MKC; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Mendis S; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Denroche RE; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Jang GH; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Kalloger SE; Pancreas Centre BC, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Wong HL; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Moore RA; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., Mungall AJ; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada., O'Kane GM; University Health Network, University of Toronto, Toronto, Ontario, Canada., Knox JJ; University Health Network, University of Toronto, Toronto, Ontario, Canada., Gallinger S; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; University Health Network, University of Toronto, Toronto, Ontario, Canada., Loree JM; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Mager DL; Terry Fox Laboratory, BC Cancer, Vancouver, British Columbia, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada., Laskin J; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Marra MA; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada., Jones SJM; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada., Schaeffer DF; Pancreas Centre BC, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada., Renouf DJ; Pancreas Centre BC, Vancouver, British Columbia, Canada. drenouf@bccancer.bc.ca.; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2020 Sep; Vol. 19 (9), pp. 1889-1897. Date of Electronic Publication: 2020 Jun 09. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
